• Je něco špatně v tomto záznamu ?

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD

AD. Ho, J. Schetelig, T. Bochtler, M. Schaich, K. Schäfer-Eckart, M. Hänel, W. Rösler, H. Einsele, M. Kaufmann, H. Serve, WE. Berdel, M. Stelljes, J. Mayer, A. Reichle, CD. Baldus, N. Schmitz, M. Kramer, C. Röllig, M. Bornhäuser, C. Thiede, G....

. 2016 ; 22 (3) : 462-9. [pub] 20151110

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000881

Allogeneic hematopoietic cell transplantation (alloHCT) as a postremission therapy in patients with FLT3-ITD-positive intermediate-risk acute myeloid leukemia (AML) remains controversial. FLT3-ITD mutations are heterogeneous with respect to allelic ratio, location, and length of the insertion, with a high mutant-to-wild-type ratio consistently associated with inferior prognosis. We retrospectively analyzed the role of alloHCT in first remission in relationship to the allelic ratio and presence or absence of nucleophosmin 1 mutations (NPM1) in the Study Alliance Leukemia AML2003 trial. FLT3-ITD mutations were detected in 209 patients and concomitant NPM1 mutations in 148 patients. Applying a predefined cutoff ratio of .8, AML was grouped into high- and low-ratio FLT3-ITD AML (HR(FLT3-ITD) and LR(FLT3-ITD)). Sixty-one patients (29%) were transplanted in first remission. Overall survival (OS) (HR, .3; 95% CI, .16 to .7; P = .004) and event-free survival (EFS) (HR, .4; 95% CI, .16 to .9; P = .02) were significantly increased in patients with HR(FLT3-ITD) AML who received alloHCT as consolidation treatment compared with patients who received consolidation chemotherapy. Patients with LR(FLT3-ITD) AML and wild-type NPM1 who received alloHCT in first remission had increased OS (HR, .3; 95% CI, .1 to .8; P = .02) and EFS (HR, .2; 95% CI, .1 to .8; P = .02), whereas alloHCT in first remission did not have a significant impact on OS and EFS in patients with LR(FLT3-ITD) AML and concomitant NPM1 mutation. In conclusion, our results provide additional evidence that alloHCT in first remission improves EFS and OS in patients with HR(FLT3-ITD) AML and in patients with LR(FLT3-ITD) AML and wild-type NPM1.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000881
003      
CZ-PrNML
005      
20200720134858.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbmt.2015.10.023 $2 doi
024    7_
$a 10.1016/j.bbmt.2015.10.023 $2 doi
035    __
$a (PubMed)26551637
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ho, Anthony, $d 1948- $7 xx0250201 $u Medizinische Klinik und Poliklinik, Abteilung Innere Medizin V, Hämatologie, Onkologie und Rheumatologie, Universität Heidelberg, Heidelberg, Germany.
245    10
$a Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD / $c AD. Ho, J. Schetelig, T. Bochtler, M. Schaich, K. Schäfer-Eckart, M. Hänel, W. Rösler, H. Einsele, M. Kaufmann, H. Serve, WE. Berdel, M. Stelljes, J. Mayer, A. Reichle, CD. Baldus, N. Schmitz, M. Kramer, C. Röllig, M. Bornhäuser, C. Thiede, G. Ehninger, . ,
520    9_
$a Allogeneic hematopoietic cell transplantation (alloHCT) as a postremission therapy in patients with FLT3-ITD-positive intermediate-risk acute myeloid leukemia (AML) remains controversial. FLT3-ITD mutations are heterogeneous with respect to allelic ratio, location, and length of the insertion, with a high mutant-to-wild-type ratio consistently associated with inferior prognosis. We retrospectively analyzed the role of alloHCT in first remission in relationship to the allelic ratio and presence or absence of nucleophosmin 1 mutations (NPM1) in the Study Alliance Leukemia AML2003 trial. FLT3-ITD mutations were detected in 209 patients and concomitant NPM1 mutations in 148 patients. Applying a predefined cutoff ratio of .8, AML was grouped into high- and low-ratio FLT3-ITD AML (HR(FLT3-ITD) and LR(FLT3-ITD)). Sixty-one patients (29%) were transplanted in first remission. Overall survival (OS) (HR, .3; 95% CI, .16 to .7; P = .004) and event-free survival (EFS) (HR, .4; 95% CI, .16 to .9; P = .02) were significantly increased in patients with HR(FLT3-ITD) AML who received alloHCT as consolidation treatment compared with patients who received consolidation chemotherapy. Patients with LR(FLT3-ITD) AML and wild-type NPM1 who received alloHCT in first remission had increased OS (HR, .3; 95% CI, .1 to .8; P = .02) and EFS (HR, .2; 95% CI, .1 to .8; P = .02), whereas alloHCT in first remission did not have a significant impact on OS and EFS in patients with LR(FLT3-ITD) AML and concomitant NPM1 mutation. In conclusion, our results provide additional evidence that alloHCT in first remission improves EFS and OS in patients with HR(FLT3-ITD) AML and in patients with LR(FLT3-ITD) AML and wild-type NPM1.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    12
$a alely $7 D000483
650    _2
$a alografty $7 D064591
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x enzymologie $x genetika $x mortalita $x terapie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a jaderné proteiny $x genetika $7 D009687
650    12
$a transplantace kmenových buněk $7 D033581
650    _2
$a míra přežití $7 D015996
650    _2
$a tyrosinkinasa 3 podobná fms $x genetika $7 D051941
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Schetelig, Johannes $u Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany. Electronic address: johannes.schetelig@uniklinikum-dresden.de.
700    1_
$a Bochtler, Tilmann $u Medizinische Klinik und Poliklinik, Abteilung Innere Medizin V, Hämatologie, Onkologie und Rheumatologie, Universität Heidelberg, Heidelberg, Germany.
700    1_
$a Schaich, Markus $u Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany.
700    1_
$a Schäfer-Eckart, Kerstin $u Klinik für Innere Medizin 5, Schwerpunkt Onkologie/Hämatologie, Klinikum Nürnberg Nord, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany.
700    1_
$a Hänel, Mathias $u Klinik für Innere Medizin III, Klinikum Chemnitz gGmbH, Chemnitz, Germany.
700    1_
$a Rösler, Wolf $u Medizinische Klinik 5 - Hämatologie und Internistische Onkologie, Universitätsklinikum Erlangen, Erlangen, Germany.
700    1_
$a Einsele, Hermann $u Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
700    1_
$a Kaufmann, Martin $u Abteilung für Hämatologie, Onkologie und Palliativmedizin, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
700    1_
$a Serve, Hubert $u Medizinische Klinik II, Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt, Germany.
700    1_
$a Berdel, Wolfgang E $u Medizinische Klinik und Poliklinik A, Universitätsklinikum Münster, Münster, Germany.
700    1_
$a Stelljes, Matthias $u Medizinische Klinik und Poliklinik A, Universitätsklinikum Münster, Münster, Germany.
700    1_
$a Mayer, Jiri $u Department of Hemato-Oncology, University Hospital Brno, CEITEC Masaryk University, Brno, Czech Republic.
700    1_
$a Reichle, Albrecht $u Klinik und Poliklinik für Innere Medizin III, Universitätsklinikum Regensburg, Regensburg, Germany.
700    1_
$a Baldus, Claudia D $u Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Schmitz, Norbert $u Abteilung für Hämatologie, Onkologie und Stammzelltransplantation, Asklepios Klinik St. Georg, Hamburg, Germany.
700    1_
$a Kramer, Michael $u Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany.
700    1_
$a Röllig, Christoph $u Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany.
700    1_
$a Bornhäuser, Martin $u Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany.
700    1_
$a Thiede, Christian $u Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany.
700    1_
$a Ehninger, Gerhard $u Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany.
700    1_
$a ,
773    0_
$w MED00008579 $t Biology of blood and marrow transplantation journal of the American Society for Blood and Marrow Transplantation $x 1523-6536 $g Roč. 22, č. 3 (2016), s. 462-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26551637 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20200720134857 $b ABA008
999    __
$a ok $b bmc $g 1180021 $s 961448
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 22 $c 3 $d 462-9 $e 20151110 $i 1523-6536 $m Biology of blood and marrow transplantation $n Biol Blood Marrow Transplant $x MED00008579
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace